IPOX® CEO Josef Schuster was quoted in a recent Reuters article, "Cybersecurity firm SailPoint sets sights on $12.6 billion valuation in US IPO", providing expert insight into SailPoint's IPO and the broader implications for the technology IPO market.

Robust global IPO activity across multiple sectors: Significant US listings include SailPoint, projecting an $11.5B valuation, and DailyPay, targeting $3-4B. Honeywell's planned spin-offs represent a notable corporate restructuring. European markets are active, featuring Novo Banco and CurrentBody. In Asia, MMC Port's anticipated $1.34B Malaysian IPO highlights the region's strength. The Middle East maintains a positive outlook, with Saudi Arabia driving deal flow.

IPOX® Research Analyst Lukas Muehlbauer offered his perspective on the market debut of Maze Therapeutics (MAZE.O), a drug developer focused on chronic kidney diseases. Maze's shares saw a modest 1% increase on its Nasdaq debut, valuing the company at $690.37 million. The company’s debut follows an upsized IPO that raised $140 million.

Large potential IPOs are emerging across regions. In the US, Silvus considers a $5B valuation IPO, while Histosonics aims for a multi-billion dollar valuation. SailPoint eyes a $1B Nasdaq return. Europe sees EcoCeres planning a $5B IPO and HBX Group with strong book coverage for its Amsterdam listing.

IPOX® Research Analyst Lukas Muehlbauer offered his expert perspective on the market debut of Metsera, a GLP-1 weight-loss drug developer that achieved a $2.7 billion valuation following a 42% surge in its Nasdaq IPO. Metsera's strong performance underscores the robust investor appetite within the innovative obesity therapeutics sector.

US IPO market shows signs of heating up in early 2025 with notable confidential filings like Voyager Technologies in space and defense ($2-3B valuation). Odyssey Therapeutics (biotech), SailPoint (cybersecurity), and Metsera (obesity drugs) have also filed for IPOs on Nasdaq. While January saw a slow start, NYSE anticipates a robust IPO market recovery driven by a strong economy and potentially lower interest rates, suggesting a positive outlook for US listings in the coming months.

IPOX® CEO Josef Schuster told Reuters that Venture Global's IPO "low float" presents a "significant risk," underscoring a challenging environment for energy IPOs to achieve high premiums and highlighting the importance of float considerations in new listings.

IPOX® CEO Josef Schuster told Bloomberg that Venture Global's IPO valuation cut "jolts" the market, signaling a crucial shift: investors now demand realistic valuations and rigorous IPO deal scrutiny, emphasizing increased investor discipline as the new norm.

IPOX® Research Analyst Dr. Lukas Muehlbauer, offered his perspective on the upcoming US IPO of Ascentage Pharma, a Chinese biopharmaceutical firm targeting a valuation of $1.75 billion. Ascentage, backed by Takeda Pharmaceutical, is seeking a US listing after its shares have already been trading on the Hong Kong stock exchange since 2019.

IPOX® CEO Josef Schuster shared his insights on the upcoming IPO of Smithfield Foods, which aims for a valuation of up to $10.73 billion. The pork producer's return to the U.S. stock market after over a decade is one of the first major consumer IPOs of the year, potentially setting a precedent for other companies in the sector.

U.S. IPO activity is picking up with eToro's potential $5 billion+ and Klarna's possible $20 billion IPO. Titan America aims to raise over $500 million. In Asia, LG CNS priced its IPO at $823 million, and Guming Holdings targets $300 million in Hong Kong. Europe sees HBX Group's €725 million IPO. Riyad Capital's potential $2.5 billion IPO leads activity in MENA.

IPOX® CEO Josef Schuster spoke with Bloomberg about the expected rebound in US energy IPOs, driven by companies like Venture Global. Schuster noted rising commodity prices and recent IPO successes create a favorable environment, adding that the market is "ready for a slew of good energy IPOs."

IPO activity is picking up globally, with the US seeing filings from biotech firms like Maze and Metsera. Europe anticipates large listings from Stada and HBX Group, while Shein and Shawbrook consider London. In Asia, NTT plans a Singapore REIT IPO, and several Chinese firms eye Hong Kong, though CATL's faces US blacklisting concerns. LG CNS launched its IPO in South Korea, while K Bank canceled its attempt. Saudi Tabreed is planning a potential Riyadh IPO.